You are here

Article Text

Article menu
Download PDFPDF
Letters
Serum immune complex containing thrombospondin-1: a novel biomarker for early rheumatoid arthritis
  1. Kaname Ohyama1,2,
  2. Atsushi Kawakami3,
  3. Mami Tamai3,
  4. Miyako Baba1,
  5. Naoya Kishikawa1,
  6. Naotaka Kuroda1
  1. 1Department of Environmental and Pharmaceutical Sciences, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan
  2. 2Nagasaki University Research Centre for Genomic Instability and Carcinogenesis (NRGIC), Nagasaki, Japan
  3. 3Unit of Translational Medicine, Department of Immunology and Rheumatology, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan
  1. Correspondence to Naotaka Kuroda, Department of Environmental and Pharmaceutical Sciences, Graduate School of Biomedical Sciences, Nagasaki University, 1-14 Bunkyo-machi, Nagasaki 852-8521, Japan; n-kuro{at}nagasaki-u.ac.jp

https://doi.org/10.1136/annrheumdis-2012-201305

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    The diagnosis of rheumatoid arthritis (RA) is based on classification criteria set by the 2010 RA classification criteria including serological assessment of rheumatoid factor (RF) and anticitrulline-containing protein/peptide (anti-CCP) antibody.1 ,2 Anti-CCP antibody is specific (94–99%) for RA; however, 25% of patients with established RA and 40% of patients with early RA are negative for this marker.3 ,4 Novel biomarkers, especially for early RA and/or for RA lacking RF and anti-CCP antibody markers (ie, seronegative RA) are therefore urgently required. Circulating immune complexes (CICs) present in the human body are likely to contain many different antigens that may reflect underlying disease, so antigens incorporated into CICs are promising candidates for diagnostic biomarkers. We developed a novel proteomic strategy (immune complexome analysis) to identify and profile antigens in …

    View Full Text

    Footnotes

    • Funding This work was supported by Special Coordination Funds for Promoting Science and Technology from Japan Science and Technology Agency, a Grant-in-Aid for Young Scientist (B; grant no. 22790160), Challenging Exploratory Research (grant no. 23659301) and Scientific Research (C; grant no. 23591439) from the Ministry of Education, Culture, Sports, Science and Technology of Japan.

    • Competing interests None.

    • Ethics approval This study was conducted with the approval of the Institutional Review Board of Nagasaki University.

    • Provenance and peer review Not commissioned; externally peer reviewed.